BioNTech SE (BNTX) Income from Non-Controlling Interests (2018 - 2022)
BioNTech SE (BNTX) posted Income from Non-Controlling Interests of $17710.2 for Q4 2019, down 87.26% sequentially from $138973.0 in Q4 2018, and down 87.26% YoY from $138973.0 in Q4 2018.
BioNTech SE (BNTX) Income from Non-Controlling Interests (2018 - 2022) Analysis & Trends
BioNTech SE has reported Income from Non-Controlling Interests for 2 years, with the latest figure at $17710.2 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 10.99 Mn |
| Jun 30, 2022 | 10.46 Mn |
| Mar 31, 2022 | 4.04 Mn |
| Dec 31, 2021 | -7.21 Mn |
| Sep 30, 2021 | 3.42 Mn |
| Jun 30, 2021 | 1.32 Mn |
| Mar 31, 2021 | 5.43 Mn |
| Dec 31, 2019 | 17,710.20 |
| Dec 31, 2018 | 138,973.00 |
| Sep 30, 2018 | -54,667.07 |